Disufenton Sodium

地舒芬通钠

Report date: 2025/05/30 11:13:41
NME

Base Information

Drug NameDisufenton Sodium
Drug Alias Namedisufenton sodiquedisufentonum natricumDisufentonOklahoma Nitrone 007CPI-22 +[11] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionOxygen radical scavengersSulfatases inhibitors
TargetsSulfatases
Therapy Area/IndicationsStrokeCerebral HemorrhageIschemic Attack, Transient +[10] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[31] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaDiscontinued
Originator CompaniesOklahoma Medical Research Foundation
China Registration ClassN/A

Develop Information

Active CompaniesGtreeBNTThe University Of OklahomaOblato Inc
Inactive CompaniesAstrazeneca Uk LtdAstrazeneca PlcOtologic Pharmaceutics Inc
Active IndicationsOligodendrogliomaGlioblastomaAstrocytoma +[4] 
Inactive IndicationsStrokeCerebral HemorrhageIschemic Attack, Transient +[6] 

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG